ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Cancer center directors to develop blueprint for progress that’s “honest,” M.D. Anderson’s John Mendelsohn says.

November 23, 2005

FDA Issues MedWatch Warning, Begins Safety Review Of Prostate Cancer Drugs

May 7, 2010

“Inoperable” Prostate Cancer May Be Operable, Curable

April 29, 2005

Varmus Appoints Group On Intellectual Property

May 8, 1998

PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.

February 29, 2008

Two activists Are Appointed To Complete NCAB

May 31, 1991